Effectiveness and safety of repeat courses of hylan G-F 20 in patients with knee osteoarthritis

被引:34
|
作者
Raynauld, JP
Goldsmith, CH
Bellamy, N
Torrance, GW
Polisson, R
Belovich, D
Pericak, D
Tugwell, P
机构
[1] Univ Montreal, Dept Med, Montreal, PQ H3C 3J7, Canada
[2] McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada
[3] St Josephs Healthcare, Ctr Evaluat Med, Hamilton, ON, Canada
[4] Univ Queensland, CONROD, Fac Hlth Sci, Brisbane, Qld, Australia
[5] Innovus Res Inc, Burlington, ON, Canada
[6] Genzyme Corp, Cambridge, MA USA
[7] Univ Ottawa, Ctr Global Hlth, Inst Populat Hlth, Ottawa, ON, Canada
关键词
hylan G-F 20; osteoarthritis; repeat courses; effectiveness;
D O I
10.1016/j.joca.2004.10.018
中图分类号
R826.8 [整形外科学]; R782.2 [口腔颌面部整形外科学]; R726.2 [小儿整形外科学]; R62 [整形外科学(修复外科学)];
学科分类号
摘要
Objective: To compare the effectiveness and safety of repeat treatment with hylan G-F 20 based on data from a randomized, controlled trial [Raynauld JP, Torrance GW, Band PA, Goldsmith CH, Tugwell P, Walker V, et al. A prospective, randomized, pragmatic, health outcomes trial evaluating the incorporation of hylan G-F 20 into the treatment paradigm for patients with knee osteoarthritis (Part 1 of 2): clinical results. Osteoarthritis Cartilage 2002;10:506-17]. The hypotheses tested were whether the single-course and repeat-course subgroups would be superior to appropriate care and not different from each other. Method: A total of 255 patients with knee osteoarthritis were randomized to "appropriate care with hylan G-F 20" or "appropriate care without hylan G-F 20". The hylan G-F 20 group was partitioned into two subgroups: (1) patients who received a single course of hylan G-F 20; and (2) patients who received two or more courses of hylan G-F 20. Results: For the primary effectiveness measure, change in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain score as a percent of baseline, the single-course subgroup improved by 41%, the repeat-course subgroup by 35%, and the appropriate care group by 14%. Both subgroups improved significantly more than the appropriate care group (P < 0.05), and were not statistically significantly different from each other (70% power to detect a 20% difference). Secondary effectiveness measures showed similar results. In the repeat-course subgroup, no statistically significant differences were found in the number of local adverse events, the number of patients with local adverse events, or arthrocentesis rates between the first and repeat courses of treatment. Conclusions: Although the study was neither designed nor powered to examine repeat treatment, this a posteriori analysis provides support for a favorable effectiveness and safety profile of hylan G-F 20 in repeat course patients. (C) 2004 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:111 / 119
页数:9
相关论文
共 50 条
  • [31] Role of hylan G-F 20 in treatment of osteoarthritis of the hip joint
    Vad, VB
    Sakalkale, D
    Sculco, TP
    Wickiewicz, TL
    ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION, 2003, 84 (08): : 1224 - 1226
  • [32] Comparison of efficacy of hyaluronan and hylan G-F 20 in osteoarthritis.
    Sripada, P
    Pritchard, C
    Bankes, PF
    ARTHRITIS AND RHEUMATISM, 1999, 42 (09): : S296 - S296
  • [33] The role of viscosupplenentation with hylan G-F 20 (Synvisc(R)) in the treatment of osteoarthritis of the knee: A Canadian multicenter trial comparing hylan G-F 20 alone, hylan G-F 20 with non-steroidal anti-inflammatory drugs (NSAIDs) and NSAIDs alone
    Adams, ME
    Atkinson, MH
    Lussier, AJ
    Schulz, JI
    Siminovitch, KA
    Wade, JP
    Zummer, M
    OSTEOARTHRITIS AND CARTILAGE, 1995, 3 (04) : 213 - 225
  • [34] Intra-articular hylan G-F 20 (Synvisc®) in the management of patellofemoral osteoarthritis of the knee (POAK)
    Clarke, S
    Lock, V
    Duddy, J
    Sharif, M
    Newman, JH
    Kirwan, JR
    KNEE, 2005, 12 (01): : 57 - 62
  • [35] Safety and efficacy of intra-articular injections of hylan G-F 20 in patients with symptomatic hip osteoarthritis
    Conrozier, T
    Bertin, P
    Mathieu, P
    Charlot, J
    Bailleul, F
    Treves, R
    Vignon, E
    Chevalier, X
    OSTEOPOROSIS INTERNATIONAL, 2002, 13 : S61 - S61
  • [36] Prospective study of the safety and efficacy of hylan G-F 20 (Synvisc®) in patients with symptomatic ankle osteoarthritis.
    Witteveen, A. g. h.
    Giannini, S.
    Guido, G.
    Jerosch, J.
    Lohrer, H.
    van Dijk, C. N.
    ARTHRITIS AND RHEUMATISM, 2006, 54 (09): : S676 - S676
  • [37] Hylan G-F 20: Review of its Safety and Efficacy in the Management of Joint Pain in Osteoarthritis
    Migliore, A.
    Giovannangeli, F.
    Granata, M.
    Lagana, B.
    CLINICAL MEDICINE INSIGHTS-ARTHRITIS AND MUSCULOSKELETAL DISORDERS, 2010, 3 : 55 - 68
  • [38] Efficacy and Safety of Hylan G-F 20 for Symptomatic Glenohumeral Osteoarthritis: A Prospective, Pilot Study
    Brander, Victoria Anne
    Gomberawalla, Ameer
    Chambers, Michelle
    Bowen, Mark
    Nuber, Gordon
    PM&R, 2010, 2 (04) : 259 - 267
  • [39] Treatment of intraarticular osteoarthritis of the knee with hylan G-F 20: comment on the article by Brandt et al
    Parenti, D
    Murray, CW
    ARTHRITIS AND RHEUMATISM, 2001, 44 (06): : 1470 - 1471
  • [40] Open-label multicenter trial of the safety and efficacy of viscosupplementation with hylan G-F 20 (Synvisc) in primary osteoarthritis of the knee
    Wobig, M
    Beks, P
    Dickhut, A
    Maier, R
    Vetter, G
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 1999, 5 (06) : S24 - S31